Is Kodiak Sciences’ (KOD) Shift Into Russell Growth Indices Reframing Its Core Investment Story?
Kodiak Sciences (KOD) recently shifted from Russell value and microcap indices to growth indices, including the Russell 2000 Growth and Russell 3000 Growth benchmarks. While this reclassification alters the stock's holder base, it doesn't change the fundamental investment narrative, which revolves around converting its ophthalmology pipeline into commercial revenue before its cash runway depletes. The company still faces significant risks, including ongoing losses and a "going concern" warning, despite some investor optimism and widely varying fair value estimates.
If You Invested $1,000 in Kodiak Sciences Inc. (KOD)
This article examines the historical performance of Kodiak Sciences Inc. (KOD) stock for investors, detailing what a $1,000 investment would be worth over different periods. It highlights the company's focus as a precommercial, retina-focused biotechnology firm with a pipeline of late-stage clinical programs for serious eye diseases. The report also describes Kodiak Sciences' proprietary ABC Platform and its investigational therapies: Tarcocimab, KSI-501, and KSI-101.
[Form 4] Kodiak Sciences Inc. Insider Trading Activity
Kodiak Sciences Inc. director Richard S. Levy was granted 17,731 stock options with an exercise price of $38.96 per share, expiring on June 29, 2036. These options will vest on the earlier of June 30, 2027, or one day before the next annual shareholder meeting, provided Levy remains on the board. This transaction was reported in a Form 4 filing accepted by the SEC on July 2, 2026.
Director at Kodiak Sciences (KOD) receives 17,731 stock options award
Kodiak Sciences Inc. director Robert Profusek was granted 17,731 stock options with an exercise price of $38.96 per share, expiring on June 29, 2036. These options will fully vest on the earlier of June 30, 2027, or the day before the company's next annual meeting, provided he remains on the board. Following this transaction, Profusek directly holds 17,731 derivative securities.
Form 4 Kodiak Sciences Inc For: 2 July By Investing.com
Investing.com reported on a Form 4 filing for Kodiak Sciences Inc. for July 2nd. The article provides the company name and filing date, alongside various market data and other news headlines, suggesting a brief update on financial regulatory disclosures related to Kodiak Sciences.
17,731 Kodiak Sciences (KOD) options granted tied to Baker funds
Kodiak Sciences director Felix J. Baker was granted 17,731 non-qualified stock options with a strike price of $38.96 per share, which are linked to Baker-affiliated funds. These options, vesting on the earlier of one year post-grant or before the next annual meeting, are issued under the company's 2018 Equity Incentive Plan and expire on June 29, 2036. Baker Bros. Advisors LP manages the voting and investment power for these options on behalf of the funds, disclaiming direct beneficial ownership for Julian and Felix Baker beyond their pecuniary interest.
Kodiak Sciences Inc.(NasdaqGM:KOD) added to Russell Small Cap Comp Growth Benchmark
Kodiak Sciences Inc. (NasdaqGM:KOD) has been added to the Russell Small Cap Comp Growth Benchmark, impacting its previous classifications within other Russell indices. The company, a precommercial retina-focused biotechnology firm, is developing three late-stage clinical programs for retinal diseases. Its stock saw a significant 5.01% increase on June 29th, reflecting positive market reaction to these changes.
Kodiak Sciences Inc.(NasdaqGM: KOD) added to Russell 3000E Growth Benchmark
Kodiak Sciences Inc. (NasdaqGM: KOD) has been added to the Russell 3000E Growth Benchmark. This news follows several other index-related announcements for the company on the same day, including additions to Russell Small Cap Comp Growth and Russell 2000 Growth benchmarks, and removals from Value benchmarks. The company is a precommercial retina-focused biotechnology firm, developing late-stage clinical programs for retinal diseases.
Enterprise value to EBIT forward of Kodiak Sciences Inc – NASDAQ:KOD
This article provides an enterprise value to EBIT forward for Kodiak Sciences Inc (NASDAQ: KOD). It lists the company's stock information, along with various financial and community features available on the TradingView platform. The content primarily focuses on presenting a specific financial metric for the company within the TradingView interface.
Enterprise value to EBITDA forward of Kodiak Sciences Inc – NASDAQ:KOD
This article provides access to the enterprise value to EBITDA forward financial metric for Kodiak Sciences Inc., trading under the NASDAQ symbol KOD. It indicates that the market is currently closed with no trades. The content is primarily a data placeholder within a financial platform, showing how users could access this specific valuation metric.
Enterprise value to revenue forward of Kodiak Sciences Inc – NASDAQ:KOD
This article displays the forward enterprise value to revenue for Kodiak Sciences Inc. (NASDAQ: KOD). The data indicates that the market was closed at the time of publication, with no trades reported.
Price to earnings forward of Kodiak Sciences Inc – NASDAQ:KOD
This article provides financial data for Kodiak Sciences Inc (NASDAQ: KOD), specifically its price-to-earnings forward ratio. The content states that the market was closed at the time of publication, and no trades were made. It appears to be a stub or a data point from a financial platform like TradingView.
Kodiak Sciences, Inc. Actuals & Estimates (NASDAQ:KOD)
This article provides an overview of Kodiak Sciences Inc. (NASDAQ: KOD) stock, detailing its current price, historical performance, analyst forecasts, and financial data. It highlights the company's market capitalization, upcoming earnings report date, and recent revenue and net income figures, while also noting that KOD does not pay dividends.
KOD - Kodiak Sciences Inc Options
This article provides a comprehensive overview of Kodiak Sciences Inc. (KOD) stock performance and financial data. It includes key metrics such as market capitalization, income, sales, P/E ratios, insider and institutional ownership, profitability, and various performance indicators. The data highlights recent stock changes, analyst recommendations, and upcoming earnings information for the biotechnology company.
KOD - Kodiak Sciences Inc Volatility & Greeks
This article provides a detailed financial snapshot of Kodiak Sciences Inc (KOD), including its market capitalization, income, sales, key financial ratios, stock performance metrics, and analyst recommendations. It highlights the company's significant year-over-year stock performance and various volatility indicators. The data provides a comprehensive overview for investors interested in KOD's current financial health and market position.
Kodiak Sciences Inc (KOD) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article provides an earnings forecast for Kodiak Sciences Inc (KOD), based on analysis from 7 analysts. The current target price for KOD is USD 64.000, representing a 79.22% upside, with most analysts recommending a "Buy" trend. The report also details past EPS performance and future expectations, noting that the company's previous EPS was USD -1.04 against an expectation of USD -0.94, and the next quarter's EPS is expected to be USD -0.96.
Kodiak Sciences Inc (KOD) Financial Health: Profitability & Balance Sheet Analysis
This article provides an analysis of Kodiak Sciences Inc.'s (KOD) financial health, focusing on profitability and balance sheet metrics. It notes that relevant data for Quality of Earnings, Operational Efficiency, Growth Potential, and Shareholder Returns have not yet been disclosed by the company. The current market data shows Kodiak Sciences Inc. trading at $36.140 with a market cap of $2.23B.
Kodiak Sciences Inc (KOD) Valuation: PE, PB & Fair Value Analysis
This article provides a valuation analysis for Kodiak Sciences Inc (KOD), focusing on key metrics like P/E, P/B, P/S, and P/CF ratios. The analysis indicates that relevant data for these valuation metrics has not yet been disclosed by the company. It serves as a brief overview of the company's current stock performance and highlights the absence of complete valuation data.
Kodiak Sciences Inc (KOD) Institutional Confidence
This article provides details on the institutional confidence in Kodiak Sciences Inc. (KOD), presenting data on institutional shareholdings and recent changes in those holdings. It lists key institutional investors like Baker Bros. Advisors LP and BlackRock, along with their share counts and percentage changes. The article is part of a broader analysis suite offered by TradingKey, focusing on various aspects of company performance.
Kodiak Sciences (KOD) Is Down 15.4% After Strong Zenkuda GLOW2 Data And Accelerated Filing Plans
Kodiak Sciences (KOD) experienced a 15.4% stock drop despite presenting strong Phase III GLOW2 data for its ophthalmology candidate Zenkuda and announcing accelerated regulatory filing plans. The company's investment narrative hinges on Zenkuda and its ABC platform transforming it into a sustainable ophthalmology business, supported by promising clinical results and a debt-free balance sheet. However, significant risks remain, including zero revenue, auditor-flagged going-concern uncertainty, a short cash runway, and potential dilution, leading to varied fair value estimates among investors.
Kodiak Sciences Zenkuda Trial Win Puts Cash Needs And Growth In Focus
Kodiak Sciences reported positive phase III results for its drug candidate Zenkuda in diabetic retinopathy, accelerating regulatory submissions. This success could make Zenkuda Kodiak's first commercial product, but the company faces challenges with less than one year of cash runway, making future funding and potential dilution key concerns. Investors will be watching regulatory interactions and financing moves closely as Kodiak navigates its path to commercialization against established competitors.
Kodiak Sciences CFO John Borgeson sold $1.02 million in NASDAQ:KOD shares
Kodiak Sciences CFO John Borgeson sold 30,000 shares of Kodiak Sciences Inc. (NASDAQ:KOD) common stock for a total of $1.02 million on June 4, 2026, through a pre-planned trading arrangement. Prior to the sale, Borgeson exercised options to acquire the same number of shares at a significantly lower price. Despite the CFO's sale and the stock appearing overvalued, Kodiak Sciences recently reported positive Phase 3 study results for its diabetic retinopathy treatment, leading to analyst price target increases and rating upgrades.
Kodiak Sciences CFO John Borgeson sold $1.02 million in NASDAQ:KOD shares
Kodiak Sciences CFO John Borgeson sold 30,000 shares of company stock for over $1 million on June 4, 2026, through a pre-arranged trading plan. This transaction followed his exercise of options to acquire these shares at a much lower price. The company recently reported positive results from its GLOW2 Phase 3 study for diabetic retinopathy, leading to increased price targets and an upgrade to a Buy rating from H.C. Wainwright and Chardan.
Kodiak (KOD) CFO sells 30,000 shares under 10b5-1 trading plan
Kodiak Sciences Inc. CFO, John A. Borgeson, executed an exercise-and-sell transaction involving 30,000 common shares. He acquired these shares by exercising stock options at $1.04 per share and then sold them in open-market transactions at weighted-average prices of $34.01 and $34.67 per share under a pre-arranged Rule 10b5-1 trading plan. Following these transactions, Borgeson directly holds 241,930 common shares of Kodiak Sciences.
KOD News | KODIAK SCIENCES INC (NASDAQ:KOD)
This article provides news and stock information for Kodiak Sciences Inc. (NASDAQ: KOD). It highlights a 35% stock rise over three months and announces Kodiak Sciences' participation in the 2026 Jefferies Global Healthcare Conference.
Kodiak Sciences Inc. (KOD) Presents at Jefferies Global Healthcare Conference 2026 - Slideshow
Kodiak Sciences Inc. (KOD) presented a slide deck at the Jefferies Global Healthcare Conference 2026. This article provides access to the published slide deck. The content was compiled by Seeking Alpha's transcripts team.
Kodiak Sciences (KOD) Jefferies Global Healthcare Conference 2026 Summary
Kodiak Sciences (KOD) presented updates at the Jefferies Global Healthcare Conference 2026, highlighting their three late-stage clinical assets: KSI-101, Zenkuda, and KSI-501, all targeting major causes of vision loss. Top-line data for these Phase III assets is expected in 2026, with multiple BLA filings planned for 2026–2027. The company emphasized its ABC Platform's ability to deliver rapid efficacy and extended durability, aiming to address significant unmet medical needs in the retinal therapy market.
Kodiak Stock Rises 35% in 3 Months: Here's What You Need to Know
Kodiak Sciences' stock has increased by 34.6% in the last three months, driven by investor confidence in its late-stage ophthalmology pipeline. The company reported positive data from its Phase III GLOW2 study for Zenkuda in diabetic retinopathy, with top-line data for other programs expected in late 2026 and early 2027. Kodiak also boasts a strong financial position with no debt, supporting its ongoing clinical and regulatory efforts.
Kodiak Sciences Inc. Files Form 8-K with SEC Detailing Company and Stock Information (June 2026)
Kodiak Sciences Inc. announced the results of its 2026 Annual Meeting of Stockholders, confirming the re-election of Class II directors, advisory approval of executive compensation, and ratification of PricewaterhouseCoopers LLP as the independent auditor. High shareholder turnout and strong support for all proposals indicate confidence in the company's leadership and strategic direction, potentially positively impacting the stock. The company is also no longer classified as an "Emerging Growth Company," signifying business maturation.
Kodiak Sciences (NASDAQ: KOD) 2026 meeting approves all proposals
Kodiak Sciences Inc. announced the results of its 2026 annual meeting of stockholders, where all proposed items were approved. Stockholders re-elected three Class II directors, gave advisory approval for named executive officer compensation, and ratified the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm. The meeting saw a high turnout of 88.53% of eligible common stock.
KOD (NASDAQ: KOD) scheduled sale of 30,000 shares after option exercise
Kodiak Sciences Inc. (NASDAQ: KOD) filed a Rule 144 notice for a proposed sale of 30,000 common shares resulting from an option exercise, intended for sale on June 4, 2026. The filing also documents a prior 10b5-1 sale by John Borgeson on April 2, 2026, involving 30,000 shares with proceeds of $1,197,453.00. This notice provides routine compliance disclosures regarding insider transactions.
Kodiak Stock Rises 35% in 3 Months: Here's What You Need to Know
Kodiak Sciences (KOD) stock has increased 34.6% in the last three months due to investor confidence in its late-stage ophthalmology pipeline and strong financial position. Positive Phase III GLOW2 study data for Zenkuda, a treatment for diabetic retinopathy, and advancements in other clinical programs like DAYBREAK and PEAK/PINNACLE for wet AMD and macular edema, are key catalysts. The company also maintains a strong balance sheet with no debt.
Kodiak Stock Rises 35% in 3 Months: Here's What You Need to Know
Kodiak Sciences (KOD) stock has risen 34.6% in the last three months, fueled by investor confidence in its late-stage ophthalmology pipeline, particularly Zenkuda for diabetic retinopathy. The company announced positive Phase III GLOW2 study data for Zenkuda, which is now considered approval-ready and positions Kodiak to become a revenue-generating entity. Kodiak also has other promising clinical programs, including KSI-501 and KSI-101 in late-stage development for various retinal diseases, and maintains a strong financial position with no debt.
KOD - Kodiak Sciences Inc Stock Price and Quote
This article provides a detailed stock price and quote for Kodiak Sciences Inc. (KOD), including its current trading performance, financial metrics, analyst ratings, and recent news and events. It lists key financial data like market cap, income, sales, EPS, and various performance indicators. The article also includes a history of analyst recommendations and a timeline of company news releases, along with insider transaction data.
Kodiak Sciences CEO to present at 2026 Jefferies Global Healthcare Conference on June 4
Kodiak Sciences Inc. CEO Victor Perlroth will present at the 2026 Jefferies Global Healthcare Conference in New York on June 4. The biotechnology company, focused on retinal therapeutics, is developing three late-stage clinical programs to combat major causes of blindness. The presentation will be webcast live, offering investors insight into Kodiak's progress and future plans.
Kodiak Sciences to Present at 2026 Jefferies Global Healthcare Conference
Kodiak Sciences will participate in the 2026 Jefferies Global Healthcare Conference. Dr. Victor Perlroth, Chairman and CEO of Kodiak Sciences, is scheduled to present on Wednesday, June 10, 2026, at 10:30 a.m. EDT. A live webcast of the presentation will be available on the company's investor relations website.
Kodiak Sciences CEO to speak at 2026 Jefferies healthcare event
Kodiak Sciences (Nasdaq: KOD) announced that CEO Victor Perlroth, M.D., will present at the 2026 Jefferies Global Healthcare Conference on June 4, 2026, at 11:40 a.m. ET. A live webcast and replay of the presentation will be available on the company’s investor relations website. This announcement comes amid recent mixed stock reactions to the company's clinical news and financial updates.
KOD Technical Analysis | Trend, Signals & Chart Patterns | KODIAK SCIENCES INC (NASDAQ:KOD)
Kodiak Sciences Inc. (NASDAQ: KOD) has a technical rating of 8 out of 10, indicating strong performance over the last year, outperforming 99% of other stocks and 98% within the Biotechnology industry. Despite a positive long-term trend, the short-term trend is negative, and recent price volatility suggests it's not an ideal entry point for investors. The stock is currently trading near the lows of its recent monthly range with considerable volume decrease observed in the last days.
Kodiak Sciences Inc stock (US50012K1051): earnings loss widens as biotech pushes retina pipeline
Kodiak Sciences Inc. reported widening losses for Q4 2025, with an EPS loss of -0.94 USD, slightly missing analyst expectations. As a clinical-stage biopharmaceutical company, Kodiak is heavily investing in its ophthalmology pipeline, focusing on therapies for retinal diseases like age-related macular degeneration. The company's valuation remains tied to clinical trial progress, regulatory approvals, and access to capital rather than current revenues, highlighting the high-risk, high-reward nature for investors in the biotech sector.
Kodiak Sciences Inc stock (US50012K1051): what’s behind the latest volatility after eye disease setback?
Kodiak Sciences Inc. (KOD) shares are experiencing volatility due to past clinical setbacks in its eye disease therapies and ongoing pipeline restructuring. The clinical-stage biopharmaceutical company focuses on developing antibody-based treatments for retinal diseases and relies on capital markets to fund its research, as it currently has no approved products generating revenue. Investors track KOD for its potential in significant retinal disease markets, despite the high risks associated with clinical drug development.
Boxer Capital Management Boosts Kodiak Sciences Holdings in Q1 2026 - News and Statistics
Boxer Capital Management significantly increased its holdings in Kodiak Sciences during Q1 2026, purchasing an additional 225,000 shares valued at an estimated $5.81 million. This transaction brought their total stake to 1,361,000 shares, representing 6.81% of their reportable assets under management and making Kodiak Sciences their second-largest holding. Kodiak Sciences, a clinical-stage biotechnology company focused on retinal diseases, has seen its stock outperform the S&P 500 over the past year.
Kodiak Sciences Inc stock (US50012K1051): Investors eye eye-disease pipeline after latest company up
Kodiak Sciences Inc (KOD) is garnering investor attention following its recent pipeline and corporate update, which highlighted progress in its retinal disease programs. Despite previous trial setbacks, the biotech firm is now outlining next development steps for its key drug candidates. As a development-stage company, Kodiak's valuation is heavily influenced by expectations for future clinical and regulatory milestones, rather than current product revenue.
Kodiak Sciences (KOD) price target increased by 16.91% to 66.30
This article reports that the price target for Kodiak Sciences (KOD) has been increased by 16.91%, raising it to $66.30. The content provided is minimal, only stating the new price target.
Sirenia Capital (KOD) and Alex Silverstein report 3,495,000 shares (5.7%)
Sirenia Capital Management and Alex Silverstein have reported beneficial ownership of 3,495,000 shares of Kodiak Sciences Inc. common stock, representing a 5.7% stake. This stake is held by SILV Fund, Ltd., which is managed by Sirenia, and both parties filed jointly. The percentage is calculated based on 61,847,870 shares outstanding as of March 19, 2026, with shared voting and dispositive power over the shares.
Kodiak Sciences (KOD) price target increased by 16.91% to 66.30
This article reports that the price target for Kodiak Sciences (KOD) has been increased by 16.91%, raising it to $66.30. It focuses solely on this specific financial update.
Kodiak Sciences stock (US50012K1051): Q4 2025 earnings miss sparks investor focus
Kodiak Sciences Inc. reported a Q4 2025 EPS of -$0.94, missing analyst estimates by $0.01, as per its May 7, 2026 earnings release. The biotech firm, specializing in retinal therapies, continues to advance its lead candidate, KSI-301, through clinical trials, focusing on long-duration treatments for conditions like AMD and DME. Investors are anticipating the next earnings report due around May 13, 2026, for updates on its pipeline and financial status.
Chardan Capital upgrades Kodiak Sciences (KOD)
This article states that Chardan Capital has upgraded Kodiak Sciences (KOD). No further details about the upgrade or the company are provided in the given content.
H.C. Wainwright Maintains Kodiak Sciences(KOD.US) With Buy Rating, Maintains Target Price $58
H.C. Wainwright has reiterated its Buy rating for Kodiak Sciences (KOD.US) and maintained a target price of $58. This indicates the firm's continued positive outlook on the company's stock performance.
Kodiak Sciences Zenkuda Data Shifts Focus To Retinal Pipeline Value
Kodiak Sciences reported positive Phase 3 GLOW2 results for Zenkuda in diabetic retinopathy, showcasing superiority over sham treatment and strengthening its retinal pipeline. This data supports a potential multi-indication BLA submission, validating Kodiak's ABC platform. While the stock has seen significant returns, investors are now focused on execution and regulatory progress, particularly regarding Zenkuda's commercialization prospects.
A Look At Kodiak Sciences (KOD) Valuation After Positive Phase 3 GLOW2 Results For Zenkuda
Kodiak Sciences (KOD) is under scrutiny after positive Phase 3 GLOW2 results for Zenkuda, amidst a 90-day share price return of nearly 90%. While the stock trades below the average analyst target, its price-to-book ratio is significantly higher than peers and the biotech industry, with continued losses and no projected revenue for next year. The article highlights a discrepancy between valuation methods, with the P/B indicating overvaluation while a DCF model suggests it's undervalued.
